BEAM · CIK 1745999
What Beam Therapeutics Inc. told the SEC could break it.
1 self-disclosed vulnerability, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
A limited set so far — we surface every cited disclosure we’ve extracted for BEAM. More may follow as additional filings are processed.
In its own words
What could break it.
Regulatory & policy
- 2025 U.S. tariff actions (10% baseline + reciprocal tariffs, 25% Canada/Mexico, 20% China) could raise R&D input/reagent costslow
Beam imports research materials, reagents and equipment and maintains a global patent and research footprint, exposing it to 2025 U.S. trade actions. On April 2, 2025 a 10% baseline reciprocal tariff was announced on all trading partners (effective April 5) plus higher individualized reciprocal tariffs on 57 countries, on top of a 25% tariff on non-USMCA goods from Canada and Mexico and a 20% tariff on imports from China, prompting retaliatory tariffs from Canada and China. While pharmaceutical-related products received certain exemptions and Beam is pre-revenue, escalating tariffs and trade disruptions could increase the cost of its research and manufacturing inputs. Severity is low given the pharma exemptions and the company's pre-commercial stage.
“On April 2, 2025, President Trump issued an executive order announcing a “baseline” reciprocal tariff of 10% on all U.S. trading partners effective April 5, 2025, and higher individualized reciprocal tariffs on 57 countries (with certain product exemptions for pharmaceutical-related products, among others).”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
Harvard (President and Fellows of Harvard College)
“We may owe Harvard and Broad Institute success payments of up to an additional $90.0 million each.”
Cited →“We also have approximately 24 pending patent applications between the Broad Institute, Inc., UCL Business, Ltd., and Apellis Pharmaceuticals, Inc.”
Cited →UCL Business, Ltd.
“We also have approximately 24 pending patent applications between the Broad Institute, Inc., UCL Business, Ltd., and Apellis Pharmaceuticals, Inc.”
Cited →The Broad Institute, Inc.
“We may owe Harvard and Broad Institute success payments of up to an additional $90.0 million each.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch